STAT

Prominent health policy researcher plagiarized colleagues’ work, Dartmouth investigation finds

The investigation found Welch “engaged in research misconduct, namely, plagiarism, by knowingly, intentionally, or recklessly appropriating the ideas, processes, results or words of Complainants." Welch challenged the findings.

A Dartmouth College investigation has concluded that Dr. H. Gilbert Welch, one of the country’s most prominent health care policy scholars, committed research misconduct in connection with a paper published in a top medical journal.

Welch plagiarized material from a Dartmouth colleague and another researcher at a different institution, according to a letter from the college’s interim provost obtained by Retraction Watch. The material was included in a 2016 paper published by the New England Journal of Medicine. The work found that breast cancer screening was more likely to overdiagnose tumors (leading to unnecessary treatments) than pick up early cases that are destined to become life-threatening.

Welch is a well-known critic of unnecessary medical screening and interventions, and has written several popular books on the topic. He is frequently quoted in media discussions of health care costs.

A from Dartmouth says a committee assigned to investigate the allegations determined that Welch “engaged in research misconduct, namely, plagiarism, by knowingly, intentionally, or recklessly appropriating the ideas, processes, results or words of Complainants without giving them appropriate credit …”

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks